Ether Compounds for Treatment of Medical Disorders
申请人:Achillion Pharmaceuticals, Inc.
公开号:US20170057993A1
公开(公告)日:2017-03-02
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R
12
or R
13
on the A group is an ether substituent (R
32
) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.